Core Insights - Palisade Bio (PALI) is a clinical-stage biopharmaceutical company focused on developing PALI-2108, a prodrug candidate aimed at treating ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD), both of which have significant unmet medical needs [1] Company Overview - PALI-2108 is being studied for two indications related to inflammatory bowel disease (IBD), specifically targeting ulcerative colitis and fibrostenotic Crohn's disease [1]